预约演示
更新于：2025-09-12
Brimonidine Tartrate/Timolol Maleate
溴莫尼定噻吗洛尔
更新于：2025-09-12
概要
基本信息
药物类型 小分子化药 |
别名 AIBETA COMBINATION OPHTHALMIC SOLUTION、Brimonidine Tartrate and Timolol Maleate、Brimonidine/timolol + [7] |
作用方式 激动剂、拮抗剂 |
作用机制 ADRA2激动剂(肾上腺素能受体α-2家族激动剂)、β-adrenoceptors拮抗剂(β-肾上腺素能受体家族拮抗剂) |
治疗领域 |
非在研适应症- |
原研机构 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C15H16BrN5O6 |
InChIKeyQZHBYNSSDLTCRG-LREBCSMRSA-N |
CAS号70359-46-5 |
查看全部结构式(2)
关联
30
项与 溴莫尼定噻吗洛尔 相关的临床试验CTIS2023-507285-24-00
Non-inferiority Clinical Trial for Comparing the Efficacy and Tolerability of a new fixed-Combination Generic Formulation of Brimonidine 0.2%/Timolol 0.5% eye drops, solution in single-dose containers vs Combigan® eye drops, solution in Patients with Open Angle Glaucoma or Ocular Hypertension - BECRO/PS/ETHRA
CTRI/2021/12/038477
A multicentre, randomized, assessor-blinded, active controlled, parallel group, two arm, bioequivalence study with clinical endpoint to assess non-inferiority of Brimonidine tartrate 2 mg/ml & Timolol 5 mg/ml preservative-free eye drops solution (Pharmathen S.A, Greece) to Combigan (Brimonidine tartrate 2 mg/ml & Timolol 5 mg/ml) eye drops solution (Allergan Pharmaceuticals Ireland, Ireland) in the treatment of elevated intraocular pressure in adult patients with chronic open-angle glaucoma or ocular hypertension.
NCT06078592
Comparison of Efficacy and Ocular Surface Disease Assessment Between BRIDIN- PLUS® Eye Drops and COMBIGAN® Eye Drops in Glaucoma or Ocular Hypertensive Patients
100 项与 溴莫尼定噻吗洛尔 相关的临床结果
登录后查看更多信息
100 项与 溴莫尼定噻吗洛尔 相关的转化医学
登录后查看更多信息
100 项与 溴莫尼定噻吗洛尔 相关的专利（医药）
登录后查看更多信息
13
项与 溴莫尼定噻吗洛尔 相关的文献（医药）2023-09-01Advances in therapy
Randomized Multicenter Clinical Trial Comparing 0.1% Brimonidine/0.5% Timolol Versus 1% Dorzolamide/0.5% Timolol as Adjuncts to Prostaglandin Analogues: Aibeta Crossover Study.
Article
作者: Ozaki, Mineo ; Ishiyama, Sosuke ; Kuwamura, Rika ; Sunagawa, Hiromi ; Otani, Shinichiro ; Nakamura, Makoto ; Nakakura, Shunsuke ; Watanabe-Kitamura, Fumika ; Mori, Sotaro ; Inoue, Toshihiro ; Lee, Jinhee ; Tsutsui, Aika ; Kanamori, Akiyasu ; Ishida, Akiko ; Yamashita, Takehiro ; Tanito, Masaki ; Shiokawa, Minako ; Oi, Junko ; Yoshida, Akiko ; Murai, Yusuke ; Kido, Noriaki ; Sagara, Takeshi ; Abe, Hideki ; Suzuki, Katsuyoshi ; Tanabe, Hirotaka ; Aoki, Ryota ; Kurimoto, Takuji ; Matsuyama, Akiko ; Kuwayama, Yasuaki ; Sakono, Takato ; Saito, Yoshiaki ; Sameshima, Motoyasu ; Inoue, Kenji ; Inatani, Masaru ; Orii, Yusuke ; Ueda, Kaori ; Musashi, Kunihiro ; Hayashi, Ken ; Kagaya, Fumie ; Manabe, Shinichi ; Kano, Kiyoshi ; Sakono, Takuto ; Nakagawa, Satoko ; Arimura, Shogo ; Inoue, Chizuru ; Yamada-Nakanishi, Yuko ; Manabe, Kaoru ; Urahashi, Mai ; Iwasaki, Kentaro ; Takaki, Keiko
INTRODUCTION:
This multicenter, randomized, comparative, and investigator-masked crossover clinical trial sought to compare the efficacy and tolerability of fixed combinations of 0.1% brimonidine/0.5% timolol (BTFC) versus 1% dorzolamide/0.5% timolol (DTFC) as adjunctive therapies to prostaglandin analogues.
METHODS:
A total of 110 patients with open-angle glaucoma or ocular hypertension previously treated with prostaglandin analogue monotherapy were randomized to receive either BTFC or DTFC as adjunctive therapy for 8 weeks. These patients were then crossed over to the alternative treatment arm for another 8 weeks. The reduction in intraocular pressure (IOP) (primary outcome), occurrence of adverse events, ocular discomfort after instillation, and patient preference (secondary outcomes) were recorded through patient interviews.
RESULTS:
BTFC instillation for 8 weeks reduced IOP by 3.55 mmHg, demonstrating non-inferiority to DTFC instillation (3.60 mmHg; P < 0.0001, mixed-effects model). Although adverse events were rare with both combinations, patients reported greater discomfort with DTFC than with BTFC (P < 0.0001). More patients preferred BTFC (P < 0.0001) over DTFC, as BTFC caused minimal or no eye irritation.
CONCLUSION:
As BTFC offered better tolerability than DTFC with comparable reduction in IOP, we recommend it as an alternative for patients who experience ocular discomfort with DTFC-prostaglandin analogue combination therapy.
TRIAL REGISTRATION NUMBER:
jRCTs051190125.
2020-09-01American journal of ophthalmology case reports
A case of the blues: Inadvertent ocular injury from accidental instillation of blue ink
作者: Port, Alexander D ; Sippel, Kimberly C ; Brissette, Ashley R
PURPOSE:
Many consumer products and non-ophthalmic medications are packaged in plastic "eye dropper" bottles, posing a risk of accidental ocular chemical injury when these substances are mistaken for eye drops.
OBSERVATIONS:
We present the case of an elderly glaucoma patient who mistook blue stamper ink for the glaucoma medication Combigan®, and suffered ocular injury as a result.
CONCLUSIONS AND IMPORTANCE:
The packaging of non-ophthalmic products in plastic "eye dropper" bottles poses a significant risk of accidental ocular chemical injury. Elderly individuals with low vision and/or cognitive deficits may be at particular risk of accidental injury. Ophthalmologists have been calling for a greater distinction between the packaging of ophthalmic and non-ophthalmic products for over 35 years, but to date little progress has been made in this regard.
2016-07-01Pediatric dermatology
Brimonidine Toxicity Secondary to Topical Use for an Ulcerated Hemangioma
作者: Gill, Kamalvir ; Golden, Alex ; Desai, Ritu ; Tamburro, Joan ; Raimer, Patricia ; Bayart, Cheryl
Abstract:
Combigan (Allergan, Irvine, CA) is an ophthalmic solution that combines 0.2% brimonidine, a selective α‐2 adrenergic agonist, with 0.5% timolol, a nonselective β‐adrenergic antagonist. It is approved for the reduction of intraocular pressure in patients with glaucoma or ocular hypertension. There have been recent reports of successful treatment of superficial infantile hemangiomas (IHs) using Combigan topically. We report the case of a 2‐month‐old girl who developed life‐threatening brimonidine toxicity requiring intubation and mechanical ventilation secondary to central nervous system depression and apnea after topical application to an ulcerated IH.
100 项与 溴莫尼定噻吗洛尔 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 青光眼 | 日本 | 2019-09-20 | |
| 开角型青光眼 | 澳大利亚 | 2005-01-07 | |
| 高眼压症 | 澳大利亚 | 2005-01-07 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 17 | 壓鹹憲顧夢衊齋遞鬱選(遞鬱窪鑰醖繭窪範選鹹) = 餘範艱鹽夢憲襯積構築 遞觸遞獵製糧襯齋顧醖 (淵鏇顧範鹽願夢鹹鬱壓, 簾網鹹製夢壓築鏇構淵 ~ 遞願鏇鑰鹽艱鹹齋鏇獵) 更多 | - | 2013-02-06 | |||
临床4期 | 121 | 餘餘襯艱蓋積鑰製蓋願(鏇夢遞襯鹽鑰鹹鹹簾壓) = 夢願製夢鏇築觸餘範膚 醖齋製構襯構製繭餘艱 (壓築簾壓網獵淵範積憲, 2.34) 更多 | - | 2012-01-12 | |||
(Lumigan®) | 餘餘襯艱蓋積鑰製蓋願(鏇夢遞襯鹽鑰鹹鹹簾壓) = 範壓願憲築遞鹹窪廠壓 醖齋製構襯構製繭餘艱 (壓築簾壓網獵淵範積憲, 3.42) 更多 | ||||||
临床4期 | 204 | 遞襯遞醖醖製範構製醖(廠襯襯艱範蓋齋積淵鬱) = 襯築憲鑰壓範觸餘壓製 艱鏇願醖夢餘遞鏇鬱願 (簾餘廠鬱窪遞範鬱蓋襯, 2.46) 更多 | - | 2011-11-24 | |||
临床3期 | - | Fixed-combination brimonidine-timolol BID | 廠醖糧鹽鹹積築顧觸糧(壓夢鹽鹹鹽顧構願構顧) = 製蓋淵蓋簾構構蓋鏇艱 構遞壓艱襯網膚鏇淵獵 (鹽憲選觸積鑰觸糧簾壓 ) | - | 2010-04-01 | ||
临床4期 | 77 | Dorzolamide/Timolol Fixed Combination (DTFC) | 窪顧壓選蓋壓築鏇襯齋(願構蓋淵齋築鏇製糧廠): mean difference = -0.7 (95% CI, -1.0 ~ -0.3), P-Value = <0.001 | 积极 | 2010-04-01 | ||
Brimonidine/Timolol Fixed Combination (BTFC) | |||||||
临床4期 | 180 | 淵壓衊鹽夢構襯範窪廠(製艱鹹構繭鑰鑰淵網醖) = Patients on brimonidine-timolol reported less burning 構鏇襯醖夢醖壓獵窪艱 (顧壓遞製艱築艱餘膚窪 ) 更多 | - | 2009-07-01 | |||
N/A | 334 | 廠鑰網壓鏇憲蓋鬱鏇顧(齋憲積構齋製網鹹觸淵) = 廠鑰壓築醖鏇繭網廠顧 膚醖網鑰網觸齋觸築鏇 (觸顧網遞糧鏇鹹壓廠鏇, 0.7 ~ 1.9) | 积极 | 2003-05-01 | |||
N/A | - | - | 鬱膚壓鏇壓鹹觸淵糧獵(網構襯膚醖觸夢蓋餘範) = 網積鏇糧齋窪壓鹹鑰顧 廠廠築壓鹽壓簾鏇網遞 (觸觸餘積衊淵鹹構廠築, 7.3) | - | 2002-10-22 | ||
鬱膚壓鏇壓鹹觸淵糧獵(網構襯膚醖觸夢蓋餘範) = 積顧選廠網蓋築願繭襯 廠廠築壓鹽壓簾鏇網遞 (觸觸餘積衊淵鹹構廠築, 5.3) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用